• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Mind Medicine (MindMed) Inc.

    11/14/24 4:05:16 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MNMD alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    Mind Medicine (MindMed) Inc.

     

    (Name of Issuer)

     

    Common Shares, no par value per share

     

    (Title of Class of Securities)

     

    60255C885

     

    (CUSIP Number)

     

    September 30, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
      ☒ Rule 13d-1(c)
      ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 60255C885 SCHEDULE 13G

     

    1

    NAME OF REPORTING PERSONS

     

    Commodore Capital LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware, USA

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    8,176,721*

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    8,176,721*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    8,176,721*

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.9%*

    12

    TYPE OF REPORTING PERSON

     

    IA

     

    *See Item 4 for additional information.

     

     

     

     

    CUSIP No. 60255C885 SCHEDULE 13G

     

    1

    NAME OF REPORTING PERSONS

     

    Commodore Capital Master LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    8,176,721*

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    8,176,721*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    8,176,721*

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.9%*

    12

    TYPE OF REPORTING PERSON

     

    OO

     

    *See Item 4 for additional information.

     

     

     

     

    CUSIP No. 60255C885 SCHEDULE 13G

     

    Item 1. (a) Name of Issuer

     

    Mind Medicine (MindMed) Inc. (the “Issuer”)

     

    Item 1. (b) Address of Issuer’s Principal Executive Offices

     

    One World Trade Center, Suite 8500, New York, New York 10007

     

    Item 2. (a, b, c) Names of Person Filing, Address of Principal Business Office, Citizenship:
       
      This report on Schedule 13G is being filed by Commodore Capital LP, a Delaware limited partnership (the “Firm”) and Commodore Capital Master LP, a Cayman Islands exempted limited partnership (“Commodore Master”). The address for the Firm and Commodore Master is: 444 Madison Avenue, Floor 35, New York, New York 10022.

     

    Item 2. (d) Title of Class of Securities

     

    Common Shares, no par value per share (the “Common Shares”)

     

    Item 2. (e) CUSIP No.:

     

    60255C885

     

    Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person filing is a:

     

    N/A

     

     

     

     

    CUSIP No. 60255C885 SCHEDULE 13G

     

    Item 4. Ownership

     

    As reported in the cover pages to this report, the ownership information with respect to the Firm is as follows:

     

    (a) Amount Beneficially Owned: 8,176,721*

     

    (b) Percent of Class: 9.9%*

     

    (c) Number of Shares as to which such person has:

     

    (i) Sole power to vote or to direct the vote: 0

     

    (ii) Shared power to vote or to direct the vote: 8,176,721*

     

    (iii) Sole power to dispose or to direct the disposition of: 0

     

    (iv) Shared power to dispose or to direct the disposition of: 8,176,721*

     

    As reported in the cover pages to this report, the ownership information with respect to Commodore Master is as follows:

     

    (a) Amount Beneficially Owned: 8,176,721*

     

    (b) Percent of Class: 9.9%*

     

    (c) Number of Shares as to which such person has:

     

    (i) Sole power to vote or to direct the vote: 0

     

    (ii) Shared power to vote or to direct the vote: 8,176,721*

     

    (iii) Sole power to dispose or to direct the disposition of: 0

     

    (iv) Shared power to dispose or to direct the disposition of: 8,176,721*

     

    *The Firm is the investment manager to Commodore Master. As of September 30, 2024, the Firm may be deemed to beneficially own an aggregate of 8,176,721 Common Shares of the Issuer, consisting of (i) 8,000,000 Common Shares and (ii) 176,721 Common Shares underlying a warrant, which is subject to a beneficial ownership limitation of 9.99%. The foregoing excludes 1,252,054 Common Shares underlying a warrant, which is subject to a beneficial ownership limitation of 9.99%. The Firm, as the investment manager to Commodore Master, may be deemed to beneficially own these securities. Michael Kramarz and Robert Egen Atkinson are the managing partners of the Firm and exercise investment discretion with respect to these securities. Ownership percentages are based on 81,590,491 Common Shares reported as issued and outstanding as of September 30, 2024 in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 7, 2024.

     

     

     

     

    CUSIP No. 60255C885 SCHEDULE 13G

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not Applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not Applicable.

     

    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Exhibit Index

     

    1. Joint Filing Agreement dated as of March 21, 2024, by and between Commodore Capital LP and Commodore Capital Master LP (incorporated by reference to Exhibit 1 to the Schedule 13G filed with the Securities and Exchange Commission on March 21, 2024).

     

     

     

     

    CUSIP No. 60255C885 SCHEDULE 13G

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Dated: November 14, 2024
       
      Commodore Capital LP
         
      By: /s/ Michael Kramarz
      Michael Kramarz, Managing Partner
         
      Commodore Capital Master LP
         
      By: /s/ Michael Kramarz
      Michael Kramarz, Authorized Signatory

     

     

     

    Get the next $MNMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MNMD

    DatePrice TargetRatingAnalyst
    1/28/2025$23.00Outperform
    Evercore ISI
    12/20/2024$20.00Buy
    Chardan Capital Markets
    10/14/2024$20.00Outperform
    Leerink Partners
    7/24/2024$36.00Buy
    ROTH MKM
    5/29/2024$27.00Outperform
    Robert W. Baird
    4/15/2024$20.00Outperform
    Leerink Partners
    12/5/2023$9.00Buy
    Canaccord Genuity
    12/9/2022$25.00Buy
    ROTH Capital
    More analyst ratings

    $MNMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Crystal Roger

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      6/16/25 4:30:05 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Director Gryska David W

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      6/16/25 4:30:04 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Director Krebs Andreas

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      6/16/25 4:30:09 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MindMed Announces New Employee Inducement Grants

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 128,750 common shares of the Company (the "Options"), with effective grant dates of June 2, 2025 and June 9, 2025, depending on the applicable employee's respective start date. The Options have an exercise price equal to the closing price of MindMed's common shares on the last trading day on which MindMed's common shares traded prior to the date of the respective

      6/9/25 4:01:00 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MindMed to Participate in June Investor Conferences

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will participate in the following investor conferences: Jefferies Global Healthcare Conference Format: Presentation Date and Time: Thursday, June 5, 2025 at 12:50 PM ET Location: New York, NY Webcast Link: Jefferies Global Healthcare Conference H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference Format: Pre-recorded Fireside Chat Date and Time: Tuesday, June 17, 2025 at 7:00 AM ET Location: Virtual We

      5/28/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Brandi L. Roberts as its Chief Financial Officer (CFO), effective June 2, 2025. In her new role, Ms. Roberts will join MindMed's executive leadership team where she will oversee all aspects of financial strategy, capital planning, accounting, investor relations and information technology as the Company advances its clinical development and commercial priorities for its lead product candidate MM120 orally disintegrating tablet (ODT) for generalized anxiety disorder (GAD

      5/27/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evercore ISI initiated coverage on MindMed with a new price target

      Evercore ISI initiated coverage of MindMed with a rating of Outperform and set a new price target of $23.00

      1/28/25 7:14:33 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chardan Capital Markets initiated coverage on MindMed with a new price target

      Chardan Capital Markets initiated coverage of MindMed with a rating of Buy and set a new price target of $20.00

      12/20/24 7:44:37 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Leerink Partners resumed coverage on MindMed with a new price target

      Leerink Partners resumed coverage of MindMed with a rating of Outperform and set a new price target of $20.00

      10/14/24 7:36:33 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    SEC Filings

    See more
    • SEC Form S-8 filed by Mind Medicine (MindMed) Inc.

      S-8 - Mind Medicine (MindMed) Inc. (0001813814) (Filer)

      6/20/25 4:05:51 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Mind Medicine (MindMed) Inc. (0001813814) (Filer)

      6/16/25 5:00:10 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Mind Medicine (MindMed) Inc. (0001813814) (Filer)

      5/27/25 7:30:20 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care